Welcome to our dedicated page for Tempus AI SEC filings (Ticker: TEM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Tempus AI's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Tempus AI's regulatory disclosures and financial reporting.
TEM: Notice of proposed sale of Restricted Stock Units. The filing lists 13,583 Restricted Stock Units to be sold by the issuer with an effective date of 02/19/2026.
The filing also shows prior sales by James Rogers: 10,084 common shares sold on 02/19/2026 for $595,460.20 and 19,966 common shares sold on 12/11/2025 for $1,461,439.07.
TEM reported an insider sale filing to sell 870 restricted common stock units. The transaction is described as restricted stock units to be sold by the issuer on 03/01/2026.
The filing also lists a prior 10b5-1 sale of 370 common shares on 02/02/2026 with an aggregate value shown as 21,981.70.
Tempus AI, Inc. executive Thomas Edward Schoenherr, CEO of Diagnostics, reported beneficial ownership of 94,967 shares of Class A common stock in an initial insider filing. This amount includes 54,405 restricted stock units, which vest in scheduled installments through February 15, 2028, and 20,000 shares certified as earned from performance-based stock units granted on August 7, 2025. The performance-based units are scheduled to vest on August 15, 2026 after the board certified achievement of the required performance metrics on February 20, 2026.
Tempus AI, Inc. outlines in its Annual Report how it uses artificial intelligence to build “Intelligent Diagnostics” that connect lab results with each patient’s clinical data to guide treatment decisions. The company has two main product lines: Diagnostics (oncology, hereditary and other tests) and Data and applications (including Insights, Trials, Next and Algos).
Its Platform aggregates multimodal data at scale through more than 700 data connections and over 5,000 healthcare sites, producing de-identified datasets used by providers and 19 of the 20 largest pharmaceutical companies. As of December 31, 2025, contracts in its data business had Remaining Total Contract Value of more than $1.1 billion, including approximately $300.0 million of potential opt-ins, and Net Revenue Retention for Insights was about 126%.
The report highlights expansion beyond oncology into neurology and cardiology, a growing suite of algorithmic diagnostics, and acquisitions such as Ambry Genetics, Arterys and Paige to deepen hereditary testing and imaging capabilities. The aggregate market value of non‑affiliate equity was approximately $11.0 billion as of June 30, 2025, and there were 173,729,901 Class A and 5,043,789 Class B shares outstanding as of February 20, 2026.
Tempus AI reported very strong growth for Q4 and full-year 2025 while remaining unprofitable on a GAAP basis.
Revenue rose 83.4% in 2025 to $1.27 billion, driven by Diagnostics revenue of $955.4 million (up 111.5%) and Data and Applications revenue of $316.4 million (up 30.9%). Q4 revenue reached $367.2 million, also up 83.0% year over year, with gross profit of $237.7 million.
The company posted a 2025 net loss of $245.0 million but improved Adjusted EBITDA to -$7.4 million, including positive Q4 Adjusted EBITDA of $12.9 million. Tempus ended 2025 with $759.7 million in cash and marketable securities, Total Remaining Contract Value above $1.1 billion, and Net Revenue Retention of 126%. For 2026, Tempus guides to revenue of about $1.59 billion and Adjusted EBITDA of roughly $65 million.
Tempus AI, Inc. director, CEO and Chairman Eric P. Lefkofsky reported a mix of stock awards and sales involving Class A Common Stock. He acquired 263,430 shares at no cost through a grant that includes fully vested restricted stock units and performance-based stock units certified as earned.
Entities associated with Lefkofsky, including Gray Media, LLC and Blue Media, LLC, sold a combined 179,837 shares in open-market transactions under a Rule 10b5-1 trading plan. In addition, 13,587 directly held shares were sold to cover statutory tax withholding obligations tied to vesting of restricted stock units, a mandated sell-to-cover transaction rather than a discretionary sale.
Erik Phelps, EVP and Chief Administrative Officer of Tempus AI, sold a total of 9,464 shares of Class A Common Stock on February 19, 2026, in two transactions of 3,814 shares at 60.0000 per share and 5,650 shares at a weighted-average 59.0500 per share, with trades between 58.71 and 59.38. After these sales, he holds 79,816 shares of Class A Common Stock directly. Footnotes state that at least one sale was executed under a Rule 10b5-1 trading plan adopted on September 15, 2025, and that certain shares were sold to cover statutory tax withholding obligations from restricted stock unit vesting via a mandated "sell to cover" arrangement rather than as discretionary sales.
Tempus AI, Inc. Chief Accounting Officer Ryan M. Bartolucci reported two equity transactions in Class A common stock. On February 20, 2026, he acquired 12,998 shares at no cost as equity compensation. This comprises 2,998 fully vested restricted stock units for his 2025 bonus and 10,000 performance-based stock units certified as earned, which are scheduled to vest on August 15, 2026 after the board certified performance goals.
On February 19, 2026, he sold 2,902 shares at a weighted average price of $59.05 per share. According to the disclosure, this was a mandatory “sell-to-cover” transaction to satisfy statutory tax-withholding obligations on vesting RSUs, and not a discretionary sale.
Tempus AI, Inc. executive Andrew Polovin reported a mix of equity awards and related share sales in Class A common stock. He acquired 38,420 shares on February 20, 2026 at $0.00 per share through grants and vesting.
The award includes 5,120 fully vested restricted stock units as his 2025 bonus and 33,300 performance-based stock units certified as earned, with those PSUs scheduled to vest on August 15, 2026. To cover statutory tax withholding on the vesting, 8,143 shares were sold through a mandated “sell to cover” transaction, not a discretionary sale.
Additional open-market sales totaling 19,092 shares occurred on February 19–20, 2026, including transactions executed under a Rule 10b5-1 trading plan adopted on August 12, 2025. After these transactions, Polovin directly holds 126,918 Class A shares.
Tempus AI, Inc. executive Ryan Fukushima, Chief Executive Officer, Data, reported both an equity award and a related tax-sale transaction in Class A common stock. He acquired 74,993 shares at $0.00 per share as a grant/award, consisting of 8,393 fully vested restricted stock units as his 2025 bonus and 66,600 shares earned from performance-based stock units granted on August 7, 2025, after the board certified performance on February 20, 2026. Separately, he sold 9,592 shares on February 19, 2026 at a weighted average price of $59.05, in multiple trades between $58.71 and $59.38, solely to cover statutory tax withholding obligations under a mandated “sell to cover” election, not as a discretionary sale. After these transactions, he directly owned 769,347 shares, and an additional 148,808 shares were reported as indirectly owned by his spouse.